Related references
Note: Only part of the references are listed.The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years
Kristina Jenei et al.
JAMA ONCOLOGY (2021)
Colorectal cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Long-term trends in colorectal cancer: incidence, localization, and presentation
Oystein Hoydahl et al.
BMC CANCER (2020)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018)
F. Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
Dominik P. Modest et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Dirk L. Kienle et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
Prashanth Rawla et al.
GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY (2019)
Trends in the contemporary incidence of colorectal cancer and patient characteristics in the United Kingdom: a population-based cohort study using The Health Improvement Network
Lucia Cea Soriano et al.
BMC CANCER (2018)
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
Giulia Fornasier et al.
ADVANCES IN THERAPY (2018)
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database
Mohamed E. Salem et al.
EUROPEAN JOURNAL OF CANCER (2018)
Proximal shift of colorectal cancer with increasing age in different ethnicities
Lin Yang et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Impact of age and mismatch repair status on survival in colorectal cancer
Pan Li et al.
CANCER MEDICINE (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours
J. Sastre et al.
EUROPEAN JOURNAL OF CANCER (2015)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer
C. F. Jehn et al.
EUROPEAN JOURNAL OF CANCER (2014)
The ARCAD advanced colorectal cancer database-open for business
M. Buyse et al.
ANNALS OF ONCOLOGY (2012)
Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
C. F. Jehn et al.
BRITISH JOURNAL OF CANCER (2012)
Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
S. Abdelwahab et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer
Ben Tran et al.
CANCER (2011)
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status
Lorenzo Fornaro et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
J. Sastre et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer.
Sanford D. Markowitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Colorectal Cancer Treatment in Elderly Patients: An Update on Recent Clinical Studies
Federica Merlin et al.
CLINICAL COLORECTAL CANCER (2008)
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer
M. Bouchahda et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)